Poster Presentations at the AACR 2024 Annual Meeting for OBI-992 and GlycOBI™ ADC platform
2024-04-11 · OBI Pharma, Inc · original obipharma.com ↗
Title: OBI-992, a novel TROP2 targeting antibody-drug conjugate, displayed excellent antitumor efficacy in various animal models Abstract presentation number: 1893 / Poster number 23/4 PDF LINK Title: In vitro characterization of a novel TROP2-targeting antibody-drug conjugate OBI-992 Abstract presentation number: 3130 / Poster number 21/11 PDF LINK Title: Development of a novel site-specific ADC glycan platform with potential for improved in vivo efficacy and stability of the ADC in animal studies Abstract presentation number: 3149 / Poster number 21/30 PDF LINK Title: OBI-992, a novel TROP2 targeting antibody drug conjugate demonstrates superior in vivo PK/PD properties and a favorable safety profile Abstract presentation number: 7179 / Poster number 24/20 PDF LINK
The release as fetched from its publisher. obipharma.com ↗